Predicting pharmacoresistance in pediatric epilepsy.

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Approximately 20% of children with epilepsy will be pharmacoresistant. The impact of intractable epilepsy extends far beyond just the seizures to result in intellectual disability, psychiatric comorbidity, physical injury, sudden unexpected death in epilepsy (SUDEP), and poor quality of life. Various predictors of pharmacoresistance have been identified; however, accurate prediction is still challenging. Population-based epidemiologic studies show that the majority of children who develop pharmacoresistance do so relatively early in the course of their epilepsy. However, approximately one third of children who initially appear pharmacoresistant in the first few years after epilepsy onset will ultimately achieve seizure freedom without surgery. The most significant predictor that early pharmacoresistance will not remit is the presence of a neuroimaging abnormality. Such children should be strongly considered for surgical evaluation. Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)19-22
Number of pages4
JournalEpilepsia
Volume54 Suppl 2
StatePublished - May 2013

Fingerprint

Epilepsy
Pediatrics
Seizures
Sudden Death
Neuroimaging
Intellectual Disability
Psychiatry
Comorbidity
Epidemiologic Studies
Quality of Life
Wounds and Injuries
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Predicting pharmacoresistance in pediatric epilepsy. / Wirrell, Elaine C.

In: Epilepsia, Vol. 54 Suppl 2, 05.2013, p. 19-22.

Research output: Contribution to journalReview article

@article{85921067feb641d48f3b3e478a60704d,
title = "Predicting pharmacoresistance in pediatric epilepsy.",
abstract = "Approximately 20{\%} of children with epilepsy will be pharmacoresistant. The impact of intractable epilepsy extends far beyond just the seizures to result in intellectual disability, psychiatric comorbidity, physical injury, sudden unexpected death in epilepsy (SUDEP), and poor quality of life. Various predictors of pharmacoresistance have been identified; however, accurate prediction is still challenging. Population-based epidemiologic studies show that the majority of children who develop pharmacoresistance do so relatively early in the course of their epilepsy. However, approximately one third of children who initially appear pharmacoresistant in the first few years after epilepsy onset will ultimately achieve seizure freedom without surgery. The most significant predictor that early pharmacoresistance will not remit is the presence of a neuroimaging abnormality. Such children should be strongly considered for surgical evaluation. Wiley Periodicals, Inc.",
author = "Wirrell, {Elaine C}",
year = "2013",
month = "5",
language = "English (US)",
volume = "54 Suppl 2",
pages = "19--22",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Predicting pharmacoresistance in pediatric epilepsy.

AU - Wirrell, Elaine C

PY - 2013/5

Y1 - 2013/5

N2 - Approximately 20% of children with epilepsy will be pharmacoresistant. The impact of intractable epilepsy extends far beyond just the seizures to result in intellectual disability, psychiatric comorbidity, physical injury, sudden unexpected death in epilepsy (SUDEP), and poor quality of life. Various predictors of pharmacoresistance have been identified; however, accurate prediction is still challenging. Population-based epidemiologic studies show that the majority of children who develop pharmacoresistance do so relatively early in the course of their epilepsy. However, approximately one third of children who initially appear pharmacoresistant in the first few years after epilepsy onset will ultimately achieve seizure freedom without surgery. The most significant predictor that early pharmacoresistance will not remit is the presence of a neuroimaging abnormality. Such children should be strongly considered for surgical evaluation. Wiley Periodicals, Inc.

AB - Approximately 20% of children with epilepsy will be pharmacoresistant. The impact of intractable epilepsy extends far beyond just the seizures to result in intellectual disability, psychiatric comorbidity, physical injury, sudden unexpected death in epilepsy (SUDEP), and poor quality of life. Various predictors of pharmacoresistance have been identified; however, accurate prediction is still challenging. Population-based epidemiologic studies show that the majority of children who develop pharmacoresistance do so relatively early in the course of their epilepsy. However, approximately one third of children who initially appear pharmacoresistant in the first few years after epilepsy onset will ultimately achieve seizure freedom without surgery. The most significant predictor that early pharmacoresistance will not remit is the presence of a neuroimaging abnormality. Such children should be strongly considered for surgical evaluation. Wiley Periodicals, Inc.

UR - http://www.scopus.com/inward/record.url?scp=84880456769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880456769&partnerID=8YFLogxK

M3 - Review article

C2 - 23646966

AN - SCOPUS:84880456769

VL - 54 Suppl 2

SP - 19

EP - 22

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

ER -